Table 1.
Management of nivolumab-induced SCLE cases in the literature.
| Age/sex | Cancer | ICI to SCLE onset (cycles) | Positive Autoantibody serologies | SCLE treatment | SCLE response | ICI management | Tumor response |
|---|---|---|---|---|---|---|---|
| 58 y f (25) | NSCLC | 5 mo (NR) | Anti-Ro/SSA | Systemic CS, HCQ | Improvement | Rechallenge | NR |
| 72 y f (10) | Melanoma | 2 mo (post cycle 13) | ANA | Topical CS, HCQ | Improvement | Discontinuation | CR |
| Anti-Ro/SSA | |||||||
| Anti-La/SSB | |||||||
| 43 y m (10) | NSCLC | 1 mo (2) | ANA | Topical and systemic CS, HCQ | Improvement | Discontinuation | PD |
| Anti-Ro/SSA | |||||||
| 75 y m (7) | NSCLC | 2.5 mo (5) | ANA | Systemic CS | Improvement | Discontinuation | PD |
| Anti-Ro/SSA | |||||||
| 66 y f (7) | NSCLC | 12 mo (9) | ANA | Systemic CS | Resolution | Rechallenge | PD |
| Anti-Ro/SSA | |||||||
| 60 y m (27) | SCLC | 1 mo (2) | Anti-Ro/SSA | Topical and systemic CS, HCQ | Resolution | Rechallenge | PD |
| 54 y f (28) | SCLC | 20 mo (NR) | ANA | Topical CS, HCQ | Resolution | Continuation | NR |
| Anti-Ro/SSA | |||||||
| Anti-La/SSB | |||||||
| 60 y m (28) | Melanoma | 0.5 mo (NR) | ANA | Topical CS | Improvement | Continuation | NR |
| Anti-Ro/SSA |
SCLE, subacute cutaneous lupus erythematosus; ICI, immune checkpoint inhibitor; CS, corticosteroids; NSCLC, non-small cell lung carcinoma; SCLC, small cell lung carcinoma; m, male; f, female; mo, months; y, year; ANA, anti-nuclear antigen; SSA, Sjögren’s syndrome-A; SSB, Sjögren’s syndrome-B; HCQ, hydroxychloroquine; NR, not reported; CR, complete response; PD, disease progression.